Abstract:Ovarian cancer (OC) is an aggressive malignancy characterized by a complex immunosuppressive tumor microenvironment (TME). Immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy by reactivating the antitumor immune response suppressed by tumor cells. However, in the case of OC, these inhibitors have failed to demonstrate significant improvements in patient outcomes, and existing biomarkers have not yet identified promising subgroups. Consequently, there remains a pressing need to understand the interplay between OC tumor cells and their surrounding microenvironment to develop effective immunotherapeutic approaches. This review aims to provide an overview of the OC TME and explore its potential as a therapeutic strategy. Tumor-infiltrating lymphocytes (TILs) are major actors in OC TME. Evidence has been accumulating regarding the spontaneous TILS response against OC antigens. Activated T-helpers secrete a wide range of inflammatory cytokines with a supportive action on cytotoxic T-cells. Simultaneously, mature B-cells are recruited and play a significant antitumor role through opsonization of target antigens and T-cell recruitment. Macrophages also form an important subset of innate immunity (M1-macrophages) while participating in the immune-stimulation context. Finally, OC has shown to engage a significant natural-killer-cells immune response, exerting direct cytotoxicity without prior sensitization. Despite this initial cytotoxicity, OC cells develop various strategies to induce an immune-tolerant state. To this end, multiple immunosuppressive molecules are secreted to impair cytotoxic cells, recruit regulatory cells, alter antigen presentation, and effectively evade immune response. Consequently, OC TME is predominantly infiltrated by immunosuppressive cells such as FOXP3+ regulatory T-cells, M2-polarized macrophages and myeloid-derived suppressor cells. Despite this strong immunosuppressive state, PD-1/PD-L1 inhibitors have failed to improve outcomes. Beyond PD-1/PD-L1, OC expresses multiple other immune checkpoints that contribute to immune evasion, and each representing potential immune targets. Novel immunotherapies are attempting to overcome the immunosuppressive state and induce specific immune responses using antibodies adoptive cell therapy or vaccines. Overall, the OC TME presents both opportunities and obstacles. Immunotherapeutic approaches continue to show promise, and next-generation inhibitors offer exciting opportunities. However, tailoring therapies to individual immune characteristics will be critical for the success of these treatments.

Editorial: Community Series in Novel Insights into Immunotherapy Targeting Tumor Microenvironment in Ovarian Cancer: Volume I

Harnessing Tumor Immunogenomics: Tumor Neoantigens in Ovarian Cancer and Beyond

Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy

Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis

Recent advances in understanding the immune microenvironment in ovarian cancer

Editorial: The cross-talk between cancer cells and immune cells in the tumor microenvironment

Editorial: Tumor immune microenvironment topographies for prediction and evaluation: unlock the mystery of the therapeutic effects and adverse events of tumor immunotherapy

Immune Cell Population in Ovarian Tumor Microenvironment

Editorial: Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II.

Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design

Targeting tumor microenvironment in ovarian cancer: Premise and promise.

Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy

Editorial: Gastrointestinal Cancer Immunotherapy: from Drug Resistance Mechanisms to Overcoming Strategies

Abstract IA005: Regional combating of immunosuppressive forces in the ovarian tumor microenvironment

The Immunosuppressive Landscape in Tumor Microenvironment

Editorial: the Immunosuppressive Tumor Microenvironment and Strategies to Revert Its Immune Regulatory Milieu for Cancer Immunotherapy

The Immune Subtypes and Landscape of Advanced-Stage Ovarian Cancer

Revisiting Ovarian Cancer Microenvironment: a Friend or a Foe?

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy

Targeting the immune microenvironment for ovarian cancer therapy